+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Distinguishing among incretin-based therapies. Glucose-lowering effects of incretin-based therapies



Distinguishing among incretin-based therapies. Glucose-lowering effects of incretin-based therapies



Journal of Family Practice 59(9 Suppl 1): S10-S19



Extensive experience from randomized clinical trials demonstrates the efficacy of GLP-1 agonists and DPP-4 inhibitors as monotherapy and in combination with metformin and other agents, although reductions in FPG and PPG, and consequently A1C, are greater with GLP-1 agonists than with DPP-4 inhibitors. This difference may result from the pharmacologic levels of GLP-1 activity that are achieved with the GLP-1 agonists and their direct action on the GLP-1 receptor. The GLP-1 agonists have attributes that would make either of them an appropriate choice in the management of all 3 patients in our case studies, while either DPP-4 inhibitor would be an appropriate choice for Case 1. Differences in dosing, administration, safety, and tolerability should be considered.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 052664999

Download citation: RISBibTeXText

PMID: 20824235


Related references

Distinguishing among incretin-based therapies. Safety, tolerability, and nonglycemic effects of incretin-based therapies. Journal of Family Practice 59(9 Suppl 1): S20-S27, 2010

Distinguishing among incretin-based therapies. Pathophysiology of type 2 diabetes mellitus: potential role of incretin-based therapies. Journal of Family Practice 59(9 Suppl 1): S5-S9, 2010

Glucose lowering and anti-atherogenic effects of incretin-based therapies: GLP-1 analogues and DPP-4-inhibitors. Expert Opinion on Investigational Drugs 18(10): 1495-1503, 2009

Incretin pharmacology: a review of the incretin effect and current incretin-based therapies. Cardiovascular and Hematological Agents in Medicinal Chemistry 10(4): 276-288, 2012

Incretin Pharmacology A Review of the Incretin Effect and Current Incretin-Based Therapies. 2012

Blood pressure-lowering effects of incretin-based diabetes therapies. Canadian Journal of Diabetes 38(5): 364-371, 2014

Distinguishing among incretin-based therapies. Introduction. Journal of Family Practice 59(9 Suppl 1): S3-S4, 2010

Emerging incretin based therapies for type 2 diabetes: incretin mimetics and DPP-4 inhibitors. Current Diabetes Reviews 4(2): 101-109, 2008

Incretin actions and consequences of incretin-based therapies: lessons from complementary animal models. Journal of Pathology 238(2): 345-358, 2016

Distinguishing among incretin-based therapies. Patient education and self-management. Journal of Family Practice 59(9 Suppl 1): S28-S30, 2010

Incretin and incretin-based therapies. Nihon Rinsho. Japanese Journal of Clinical Medicine 68(5): 931-942, 2010

A critical analysis of the clinical use of incretin-based therapies: Are the GLP-1 therapies safe?. Diabetes Care 36(7): 2118-2125, 2013

A Critical Analysis of the Clinical Use of Incretin-Based Therapies Are the GLP-1 Therapies Safe? The benefits by far outweigh the potential risks. 2013

A Critical Analysis of the Clinical Use of Incretin-Based Therapies Are the GLP-1 Therapies Safe? How safe are the GLP-1-based therapies?. 2013

Managing recent-onset diabetes: choosing durable, well-tolerated therapies and understanding the role of incretin-based therapies. Journal of the American Osteopathic Association 114(5 Suppl 2): S6, 2014